Cancer-associated retinopathy (CAR) is a rare paraneoplastic neurological syndrome (PNS) but, when present, it is often associated with small-cell lung cancer (SCLC) (Thirkill et al., 1993) . CAR is characterised by rapid and progressive visual loss and retinal degeneration that occur in association with cancer without direct invasion or metastasis of cancer to the retina (Thirkill et al., 1989) . While the mechanism for paraneoplastic degenerative retinopathy has not been fully elucidated, the presence of peculiar antibodies in patients who suffer from this disease suggests that autoimmunity plays an important pathogenic role in the development of CAR (Thirkill et al., 1989 (Thirkill et al., , 1993 . Recently, the CAR antigen was identified as a 23 kDa photoreceptor protein, recoverin, from the screening of retinal proteins in CAR patients' sera (Polans et al., 1991; Thirkill et al., 1992) . Recoverin is specifically localised in the photoreceptor cells and participates in the recovery phase of visual excitation and in adaptation to background light (Kawamura, 1994) . While the presence of shared epitopes between retina and cancer cells, especially SCLC, had been proposed, such CAR antigen in cancer cells had not been clarified (Thirkill et al., 1989 ) until quite recently, when Polans et al. (1995 demonstrated the specific expression of recoverin in the SCLC from a patient associated with CAR. We have examined the expression of recoverin in various human lung cancer cell lines, including a cell line derived from an SCLC patient with CAR.
Materials and methods

Cell lines
Ten SCLC cell lines and four non-SCLC cell lines were used in this study. An SCLC cell line, designated MN-1112, was established from a tumour of an SCLC patient with CAR (Yamaji et al., 1996) . The patient profile had been described previously (Matsubara et al., 1996) . Briefly, the patient was a 69-year-old man who had progressive bilateral visual loss.
Funduscopical examination, brain and ocular computerised tomography and magnetic resonance imaging did not demonstrate any abnormalities. Shortly after admission, SCLC was found in the right lung. An autoantibody against rat retina in the patient's serum was also demonstrated by immunohistochemistry. Therefore, the patient was diagnosed as having CAR associated with SCLC. Two SCLC cell lines, H-69 and N-231, were obtained from Dr Futami (National Cancer Center Research Institute, Tokyo, Japan) and an SCLC cell line, LU-134-AM, and all non-SCLC cell lines were provided by the Japanese Cancer Research Resources Bank (JCRB). Other SCLC cell lines (KT-1027, TO-1019, MT-428, MN-321 and M-319) were established from patients without CAR at our laboratory (Fujita et al., 1994) .
Reverse transcribed (RT) -PCR and direct sequencing analysis A cDNA strand was synthesised from approximately 2 ,ug of total RNA and subsequently amplified by polymerase chain reaction (PCR), as previously described (Matsubara et al., 1995) . This primer pair was designed to amplify the recoverin gene between exon 1 and exon 3 of the published human recoverin sequence (Murakami et al., 1992) . The primers used for amplification from human recoverin sequence were 5'-TGT GTT CCG CAG CTT CGA TT-3'(sense) and 5'-TGA GGC TCA AAC TGG ATC AG-3'(antisense). Thirty cycles of PCR for human recoverin and 25 cycles of PCR for human fl-actin were carried out using a thermal cycler (Sanko Junyaku, Tokyo, Japan) according to the step programme of 94°C 80 s, 50°C 80 s, 72°C 80 s, followed by a 15 min extension at 72°C. After amplification, the PCR product was electrophoretically separated on a 1.5% agarose gel and stained with ethidium bromide. Another amplified PCR product (containing an entire coding region, 752 base pairs in length) was sequenced by the direct dideoxy chain termination method using a T7 sequencing kit (Pharmacia) and [35S]dATP (>37 TBq mmol -, Amersham), as previously described (Matsubara et al., 1995) . The primers used for amplification from the human recoverin sequence were 5'-CAGCTCACACCAGCCTT-3' as the sense primer at an upstream position from the start codon in exon 1 and 5'-CACGGGTGTCATGTGAG-3' as the antisense primer at a downstream position from the stop codon in exon 3. The sequencing primers were chosen from those used to generate the three nested PCR fragments.
Northern blot analysis Total RNAs from the lung cancer cell lines were extracted as described above. Approximately 10 ,ug of each RNA preparation was electrophoresed on a 0.4 M formaldehyde-1% agarose gel, transferred to a Nytran membrane (Schleicher and Shull, Keene, NH, USA) and hybridised with a nick-translated 32P-labelled PCR clone of human recoverin cDNA from MN-1112 for 24 h at 42°C (Sato et al., 1993) . After autoradiography at room temperature for 24 h, hybridisation signals were detected using a Bioimaging Analyser (BAS 1000 system, Fuji Photo Film, Tokyo, Japan). The quantity and quality of RNA on the blot were checked by hybridisation with human ,B-actin cDNA probe.
Western immunoblot analysis Confluent cultures of the ten SCLC cell lines were washed with phosphate-buffered saline (PBS) and scraped, and cells were collected and homogenised with a glass homogeniser in lysis buffer [20 mM Tris-HCl, pH 7.4, 1 mM EGTA, 0.5 mM DTT, 0.2 mm phenylmethylsulphonyl fluoride (PMSF)]. The cells were sequentially centrifuged at 1 500 g for 15 min at 4°C. Each supernatant was collected. The protein content was determined by a routine method (Fujita et al., 1994) . Each whole cell lysate of 30 ,ug, electrophoretically separated on a 10-20% gradient gel, was transferred to a Clearblot P membrane (Atto, Tokyo, Japan), which was then rinsed three times with 50 mm Tris/400 mM sodium chloride (pH 7.5) buffer containing 0.05% Tween 20. The membrane was incubated with 100 mm Tris/150 mM sodium chloride (pH 7.5) containing 2% blocking reagent (Boehringer Mannheim, IN, USA) for 3 h at room temperature, then with a 1000-fold diluted rabbit polyclonal anti-S-modulin antibody (kindly obtained from Dr Kawamura, Osaka University, Osaka, Japan) in the same buffer for 2 h. S-modulin is a frog recoverin, of which the amino acid sequence shows an 83% identity to the bovine recoverin sequence. The membrane was washed twice with the same solution for 30 min, and incubated for 1 h with a 10 000-fold diluted alkaline phosphatase-conjugated goat anti-rabbit IgG (Organon Teknika, Durham, NC, USA) in buffer containing 1% bovine serum albumin (BSA). After rinsing, blots were developed using a chemiluminescence reaction (LumiPhos 530, Boehringer Mannheim), then exposed to radiographic film for 15 (Murakami et al., 1992) .
Detection of recoverin immunoreactivities in the various human SCLC cell lines by Western blots
The expression of recoverin immunoreactivities in various SCLC cell lines was examined by Western immunoblotting using a polyclonal rabbit anti-S-modulin antibody, which was cross-reacted to the purified bovine recoverin (Figure 3) 
Discussion
The PNSs are frequently associated with SCLC, which possesses many neuronal characteristics (Greco, et al., 1981) . The neuronal characteristics of SCLC are considered to provide the antigenic stimulus required for production of a cross-reacting immune response to the nervous system targeted (Kornguth, 1989) . The expression of some candidates for PNS autoantigen, such as HuD protein for paraneoplastic encephalomyelitis (Sekido et al., 1994) or voltage-gated calcium channels for Lambert-Eaton myasthenic syndrome (Ogura-Okano et al., 1992) , has been examined in various SCLC cell lines. However, these autoantigens were expressed in almost all SCLC cell lines tested, both in the cell lines related to PNS and in those not related to PNS. In these cases, to explain rare events of PNS among the common a 20 S- expression of such autoantigens in SCLC, some genetical backgrounds in the cancer host have been proposed which regulate the susceptibility to PNS. On the other hand, in certain PNSs, such a paraneoplastic cerebellar degeneration, the patient-specific expression of neural antigens was demonstrated in tumour tissue from the patient (Furneaux et al., 1990) . In this study, we demonstrated that recoverin, the retina-specific protein, is another such antigen for PNSs. Using RT-PCR, we found the gene expression of recoverin, as a conceivable candidate for the CAR autoantigen, exclusively in only one SCLC cell line derived from a patient with CAR (Figure 1) . Its immunoreactivity was also found in only this cell line by Western immunoblotting using polyclonal anti-S-modulin antibody (Figure 3) . Thirkill et al. (1993) previously suggested that recoverin expression could be induced in otherwise quiescent SCLC cell lines. However, the expression of recoverin in an SCLC cell line, MN-1112, was not induced during the establishment and passage of the cell line because, as previously reported, the recoverin expression was immunohistochemically demonstrated in a primary SCLC tumour of the CAR patient from which the cell line was derived (Matsubara et al., 1996) .
Previous reports indicated that the presence of autoantibodies to 23 kDa CAR antigen was highly specific for cancer, especially for SCLC. Namely, there have been no reports indicating a correlation between the antibody against 23 kDa peptide and other forms of retinopathy including retinitis pigmentosa, diabetic retinopathy and age-related macular degenerations, in which a variety of antibodies are produced against-retinal antigens (Thirkill et al., 1993). Furthermore, a strong antigenicity of recoverin has already been proven by the experiment that an injection of purified recoverin into Lewis rats induced both cellular and humoral immune activation, resulting in an experimental uveoretinitis (Adamus et al., 1994; Gery et al., 1994) . Both our and these previous findings strongly suggest that the ectopic expression of recoverin in SCLC cells could sensitise T cells in the cancer host and also stimulate the production of autoantibody from B cells, then induce the degeneration of retina. However, whether a CAR patient possesses a genetically determined susceptibility to induce such an immune response remains unknown. It seems unlikely that the presence of an autoantibody only reflects a non-specific secondary response to retinal injury of other causes.
A spliced or point-mutated form of the responsible antigen expressed in the tumours has been suggested to trigger an autoimmune response in PNS (Dalmau et al., 1992) . However, our findings obtained from Northern blotting and sequencing 
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&h of recoverin in the cells revealed no alternative splicing and no point mutations in the entire coding region (Murakami et al., 1992) . This is in line with the above-mentioned animal model, in which the uveoretinitis could be experimentally induced by a purified wild-type form of recoverin.
In conclusion, our findings, together with the previous reports, strongly support the hypothesis that autoimmunity against the ectopic recoverin expressed in SCLC cells crossreacts with the corresponding antigen located in the retina and induces retinal degeneration in a CAR patient.
